ArticleJournal of extracellular biology2026
A One-Step Workflow for Size-Based Separation of Extracellular Vesicles With Integrated Surface Marker Detection.
Article in Journal of extracellular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) are released by diverse cell types in biofluids and are increasingly studied in liquid biopsies as diagnostic and prognostic biomarkers for various diseases, including cancer. Typically, the analysis of EV-associated biomarker characteristics such as size and surface markers requires pre-purification from large volumes of complex biofluids, leading to longer turnaround times and more technical variability. To overcome these limitations, we developed a one-step workflow that combines size-based separation with size and surface marker characterisation of EVs in minute volumes from different biological fluids. We coupled a multi-angle light scattering detector (MALS) and a fluorescent light detector (FLD) in-line with the asymmetrical flow field-flow fractionation (AF4) equipment. The AF4-MALS-FLD workflow was optimised to enable the analysis of EV surface markers CD9, CD63 and CD81, and cancer biomarkers PSMA, EpCAM and HER2 in samples of increasing complexity, including purified EV preparations, cell culture supernatant, urine and blood plasma. Proof-of-concept was gained for the detection of PSMA-positive EVs in urine from prostate cancer patients and discrimination of breast cancer patients from healthy donors by quantifying EpCAM- or HER2-positive EVs in blood plasma. In conclusion, using low-volume biofluids, the one-step AF4-MALS-FLD workflow holds potential for fast and robust EV biomarker detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.